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Abstract
Background: Limited data are available regarding the cost-effectiveness of preventative therapies
for postmenopausal women with osteopenia. The objective of the present study was to evaluate
the cost-effectiveness of raloxifene, alendronate and conservative care in this population.
Methods:  We developed a microsimulation model to assess the incremental cost and
effectiveness of raloxifene and alendronate relative to conservative care. We assumed a societal
perspective and a lifetime time horizon. We examined clinical scenarios involving postmenopausal
women from 55 to 75 years of age with bone mineral density T-scores ranging from -1.0 to -2.4.
Modeled health events included vertebral and nonvertebral fractures, invasive breast cancer, and
venous thromboembolism (VTE). Raloxifene and alendronate were assumed to reduce the
incidence of vertebral but not nonvertebral fractures; raloxifene was assumed to decrease the
incidence of breast cancer and increase the incidence of VTEs. Cost-effectiveness is reported in $/
QALYs gained.
Results: For women 55 to 60 years of age with a T-score of -1.8, raloxifene cost approximately
$50,000/QALY gained relative to conservative care. Raloxifene was less cost-effective for women
65 and older. At all ages, alendronate was both more expensive and less effective than raloxifene.
In most clinical scenarios, raloxifene conferred a greater benefit (in QALYs) from prevention of
invasive breast cancer than from fracture prevention. Results were most sensitive to the
population's underlying risk of fracture and breast cancer, assumed efficacy and costs of treatment,
and the discount rate.
Conclusion: For 55 and 60 year old women with osteopenia, treatment with raloxifene compares
favorably to interventions accepted as cost-effective.
Background
Osteoporosis has been operationally defined as a bone
mineral density (BMD) at least 2.5 standard deviations
below that seen in young healthy women (T-score < -2.5)
and osteopenia as a BMD T-score between -1 and -2.5[1].
Although the risk of fracture is greater in postmenopausal
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women with osteoporosis than with osteopenia, there are
far more postmenopausal women with BMD values in the
normal or osteopenic range[2]. As a result, more fractures
occur in women with osteopenia than with osteoporosis
[3-6]. Guidelines generally agree that women with oste-
oporosis should receive pharmacotherapy [7-9] for frac-
ture prevention but consensus has not been reached for
the management of women with osteopenia. With up to
50% of postmenopausal women in the US estimated to
have osteopenia,[2] the optimal approach to fracture pre-
vention in these women is a question of vital public
health interest.
Conservative care for osteopenic women includes weight-
bearing exercise and calcium/vitamin D supplementation.
Pharmacological treatment options include bisphospho-
nates and raloxifene. The effects of bisphosphonates are
largely limited to bone tissue due to their long-term incor-
poration into the bone matrix[10]. The selective estrogen
receptor modulator (SERM) raloxifene is indicated for the
prevention and treatment of osteoporosis and is also asso-
ciated with multiple extra-skeletal effects[11]. Raloxifene
differs from bisphosphonates and from other SERMs in
that the results of large clinical trials have demonstrated
that it reduces the incidence of both vertebral fractures
and breast cancer [12-14]. An important adverse event
associated with raloxifene is an increased incidence of
venous thromboembolism[15,16]. Selecting a bisphos-
phonate, raloxifene, or conservative management for
women with osteopenia requires consideration of the
benefits, risks, and costs of each option.
A recent study concluded that alendronate, a commonly
prescribed bisphosphonate, was not cost-effective relative
to conservative care for osteopenic women in the absence
of additional risk factors for fracture[17]. The effectiveness
and cost-effectiveness of raloxifene in this population
have yet to be established. To that end, we developed a
decision analytic model to examine the effectiveness and
cost-effectiveness of raloxifene and alendronate relative to
conservative care for postmenopausal women with low
bone mass who have not yet experienced a fracture.
Methods
We developed a microsimulation model to assess cost-
effectiveness from a societal perspective. The structure of
the model and additional methodological details are
included in an additional file [see Additional File 1]. We
examined clinical scenarios including postmenopausal
women without any pre-existing fractures, ranging in
starting age from 55 to 75 with BMD T-scores ranging
from -1.0 to -2.4 at the femoral neck. For each age and T-
score combination, a patient's risk of breast cancer was
assumed in the base case to be equal to the population
mean and varied in sensitivity analyses. Three manage-
ment strategies, 5 years of raloxifene, 5 years of alendro-
nate, or no drug therapy, were considered. Patients were
assumed to be 100% compliant with therapy but this
assumption was varied in sensitivity analyses. All patients
were assumed to be receiving supplemental calcium and
vitamin D. In each cycle a patient may die or incur any
one or more of four fragility fracture types (hip, vertebral,
wrist, and other), breast cancer, and/or a venous throm-
boembolism (VTE). Cohorts of 100,000 women were
simulated until age 100 or death. Age-dependent mortal-
ity was modeled using 2002 data[18]. Health states were
assigned utilities, reflecting patient preferences, from the
literature and effectiveness was assessed in quality-
adjusted life years (QALYs). Cost-effectiveness was
assessed in terms of dollars per event avoided and dollars
per QALY. Costs and outcomes were discounted at a 3%
annual rate in the base case. Key parameters and assump-
tions used in the model are summarized in Table 1 and
additional information is available in the technical
appendix.
Event incidence rates
Age and T-score dependent incidences for spine (both
radiographic and clinical), hip, wrist and other fractures
were calculated from published data[19]. We assumed
that 35% of spine fractures would be clinically appar-
ent[20]. Post-fracture risk multipliers were used to calcu-
late increased rates for subsequent fractures[21].
Following a hip fracture, 23% of the observed increase in
mortality at age 60 was assumed to be attributable to the
hip fracture event[22]. Fracture reduction efficacy for sub-
groups of women with T-scores in the osteopenic range
have been reported for both raloxifene[23] and alendro-
nate[24]. While there is disagreement about whether alen-
dronate reduces risk of vertebral fracture in osteopenic
women [24-27], we assumed that the vertebral fracture
risk reduction with alendronate that was reported for
women with osteoporosis[25] also applied to women
with osteopenia. Neither therapy has demonstrated effi-
cacy in preventing nonvertebral fractures in osteopenic
women [23-25]. After treatment cessation, residual frac-
ture reduction benefits were phased out linearly over five
years.
Five-year risks of invasive breast cancer were obtained
from the Surveillance, Epidemiology, and End Results
database[28]. Stage at diagnosis was calculated by pooling
1996–2000 with 2001–2002 data available from the
Centers for Disease Control[29]. Age-dependent breast
cancer mortalities were computed by stage at diagnosis.
The effect of raloxifene on reducing the incidence of inva-
sive breast cancer was assumed to begin in the second
year[30] and phase out over five years after raloxifene
treatment ends. Alendronate was assumed not to affect
the risk of breast cancer.BMC Women's Health 2007, 7:6 http://www.biomedcentral.com/1472-6874/7/6
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The incidence of VTE in 67 year old women eligible for
and receiving raloxifene treatment was obtained from the
placebo group of the MORE trial[15] and extrapolated to
other ages[31]. Recurrence rates for VTE were 8%[32] in
the first year and 2% in all subsequent years[33]. We
assumed 5% of VTEs were fatal[32]. Raloxifene was
assumed to confer a 6.2-fold increase in VTE incidence
during the first 2 years of raloxifene treatment, with a
return to baseline beginning in the 3rd  year of ther-
apy[15,16]. If a patient who received raloxifene experi-
enced a VTE or developed breast cancer, treatment was
immediately stopped.
Costs
Medication costs for alendronate and raloxifene reflect
April 2006 Net Wholesale Price (NWP)[34]. Other cost
estimates were obtained from published literature [35-39]
and inflated to April 2006 US dollars using the healthcare
component of the Consumer Price Index.(Table 1).
Sensitivity Analyses
Alternative scenarios were considered to understand the
importance of the duration of therapy and the patient
population's risk of fracture, breast cancer, and VTE. One-
way sensitivity analyses were used to determine the influ-
ence of other model parameters. In probabilistic sensitiv-
ity analyses (presented in the technical appendix), input
values were sampled from lognormal distributions for
event costs and generalized beta distributions for health
state utilities and the relative risk of events with treatment.
Using these distributions, 1000 samples of 1000 simu-
lated patients were analyzed.
Table 1: Key model parameters
Parameter Value
Direct medical costs, $
Raloxifene, annual cost 982 [34]
Alendronate, annual cost 880 [34]
Hip Fracture, First year 30,499
Direct Medical Costs 19,566 [36]
Long Term Care, year 1 10,933 [39]
Hip Fracture, Subsequent Years 7,723 [36]
Vertebral Fracture 8,002 [36]
Vertebral Fracture, Non-Clinical 0
Other Fracture 6,289 [36]
Wrist Fracture 4,344 [36]
Breast Cancer
Stage I, years 1–4 23,290; 7,763; 3,882; 1,086 [38]
Stage II, years 1–4 24,066; 6,287; 6,987; 7,375 [38]
Stage III, years 1–3 41,922; 47,357; 3,882 [38]
Stage IV, years 1–3 57,448; 17,079; 2,329 [38]
Fatal VTE 6,665 [37]
Non-Fatal VTE 17,034 [35]
Relative event risks with treatment
Vertebral fracture, alendronate 0.54 [25]
Vertebral fracture, raloxifene 0.53 [23]
Invasive breast cancer, raloxifene, years 2–5 0.28 [30]
VTE, raloxifene, years 1 and 2 6.2 [15]
Health state utilities
Initial utility 0.84 [55]
Relative utilities
Post fracture
Hip, year 1, years 2+ 0.792, 0.813 [56]
Vertebral, year 1, years 2+ 0.69, 0.905 [56]
Non-clinical vertebral, years 1–6 0.905 [57]
Other, year 1, years 2+ 0.896, 0.968 [56]
Wrist, year 1, years 2+ 0.976, .999 [56]
Breast cancer
Stage I, year 1, year 2–5, year 6+ 0.85, 0.91, 0.99 [58-61]
Stage II, year 1, years 2+ 0.72, 0.87 [58-61]
Stage III, year 1, years 2+ 0.62, 0.84 [58-61]
Stage IV, year 1, year 2, 3+ 0.42, 0.64, 0.84 [58-61]
Terminal 0.23 [59]
Post VTE, year 1, years 2+ 0.9, 0.986 [44]
Abbreviations: VTE, venous thromboembolism.BMC Women's Health 2007, 7:6 http://www.biomedcentral.com/1472-6874/7/6
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Results
Base case
For 60 year old women with a T-score in the middle of the
osteopenic range (-1.8) and with the population mean
risk of breast cancer and VTE, 5 years of treatment with
raloxifene has an incremental lifetime discounted cost of
$3,726 per patient. The expected net total decrease in clin-
ical vertebral fractures (22.4 fewer cases per 1,000
women) and breast cancers (23.1 fewer cases per 1,000
women) and increase in VTEs (12.1 more cases per 1,000
women) results in a lifetime discounted cost of $111,257
per event avoided. The incremental cost-effectiveness ratio
for 60 year old women in the middle of the osteopenic
range (T-score = -1.8) is approximately $50,000 per qual-
ity-adjusted life year (QALY) relative to conservative
care.(Table 2) Similar results were obtained for 55 year
old women. Raloxifene was less cost-effective for women
starting therapy at age 65 and the cost-effectiveness ratios
increased further for 70 and 75 year old women.
Under base case assumptions, alendronate therapy was
more expensive and less effective than raloxifene for all
combinations of age (55 to 75) and T-score (-1.0 to -2.4)
considered. In situations where raloxifene therapy might
not be considered a viable treatment option, such as in
patients with a history of VTE or with active neoplasms,
alendronate costs approximately $113,000/QALY com-
pared to conservative care for 60 year old women with a
T-score of -1.8.
The influence of the extra-skeletal effects with raloxifene is
summarized in Figure 1. From age 55 to 70, the increase
in quality-adjusted life expectancy from the prevention of
invasive breast cancers is greater than for fracture preven-
tion. At age 75, the increased risk of VTEs with raloxifene
offsets nearly 30% of the effects from fracture and breast
cancer prevention.
Importance of Patient Population Characteristics
The effect of T-score and risk of breast cancer on
raloxifene's cost-effectivness ratio is summarized in Figure
2. At each age, raloxifene was more cost-effective at lower
T-scores and higher risk of breast cancer. For women near
the threshold of osteoporosis (T-score = -2.4), the incre-
mental cost-effectiveness ratio with raloxifene improved
to $36,972, while for women with a T-score of -1.0, it
increased to $63,027. For 60 year old women, the cost-
effectiveness ratio for raloxifene was less than $50,000/
QALY for all osteopenic women with a 5-year risk of
breast cancer of greater than 2.25%. For 60 year old
women with a 5-year risk of breast cancer of 1.87%, which
is the age-dependent population mean risk, the cost-effec-
tiveness ratio for raloxifene was less than $50,000/QALY
when the T-score was -1.8 or worse. Raloxifene was cost-
saving in 60 year old women with over 4 times the popu-
lation relative risk of breast cancer (e.g., a woman who has
received 2 or more breast biopsies, at least 1 of which
resulted in a diagnosis of atypical hyperplasia, and 1 first
degree relative with a history of breast cancer) at a T-score
of -1.8.
Sensitivity Analyses
If the duration of raloxifene therapy was shortened to 2
years or extended to 7 years, the cost effectiveness ratio
Table 2: Incremental cost-effectiveness ratios (ICERs) for 5 years of drug therapy or no therapy, T-score = -1.8.
Cost ($) Effectiveness (QALY) ICER* ($/QALY)
Age Therapy Total ∆ Total ∆
55 Conservative care 20,342 - 14.270 - -
Raloxifene 24,169 3,827 14.351 0.081 47,247
Alendronate 24,370 201 14.303 -0.048 Dominated
60 Conservative care 16,773 - 12.747 -
Raloxifene 20,499 3,726 12.823 0.076 49,026
Alendronate 20,748 249 12.782 -0.041 dominated
65 Conservative care 13,541 - 11.131 - -
Raloxifene 17,240 3,699 11.196 0.065 56,908
Alendronate 17,471 231 11.166 -0.030 dominated
70 Conservative care 10,643 - 9.474 -
Raloxifene 14,355 3,712 9.528 0.054 68,741
Alendronate 14,513 158 9.505 -0.023 dominated
75 Conservative care 8,084 - 7.808 - -
Alendronate 11,860 3,776 7.833 0.025 dominated*
Raloxifene 11,861 3,777 7.845 0.037 102,081
The ICERs were calculated using additional significant figures in the incremental cost and QALYs. Abbreviations: QALY, quality-adjusted life year; 
ICER, incremental cost-effectiveness ratio
• dominated by extended dominance (raloxifene has greater effectiveness and a lower cost-effectiveness ratio)BMC Women's Health 2007, 7:6 http://www.biomedcentral.com/1472-6874/7/6
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increased to $71,442 or $50,944 respectively. Including
mortality attributable to vertebral fractures improved the
cost-effectiveness ratio to $45,721. Reducing compliance
with therapy to 80% or 50% increased the cost-effective-
ness ratio to $50,660 or $58,260. Although never shown
to do so in a non-osteoporotic population, if alendronate
was assumed to reduce the incidence of nonvertebral frac-
tures and the risk of breast cancer was equal to the popu-
lation mean, then alendronate was found to be more cost-
effective than raloxifene in women over the age of 60 with
a T-score of -1.9 or lower. If the price of alendronate was
reduced by over 50% to $1/day, then the cost-effective-
ness ratio compared to conservative care was $46,714 for
60 year old women with a T-score of -1.8. For a SERM with
similar efficacy as raloxifene in preventing vertebral frac-
tures but with no effect on breast cancer or VTEs, the cost
per QALY was $123,262.
Additional sensitivity analyses are summarized in Figure
3. The results were sensitive to the discount rate and ther-
apy parameters including the efficacy magnitude, efficacy
duration after treatment cessation, and medication costs.
Patient preferences for post-vertebral fracture and breast
cancer states were of moderate importance. The results
were less sensitive to the attributable mortality following
hip fracture, fracture costs, or any of the VTE parameters.
Discussion
Antiresorptive agents are considered effective in reducing
the incidence of fracture and have favorable cost-effective-
ness profiles for most postmenopausal women with oste-
oporosis[40]. Whether these mediations should be used
in patients with osteopenia is much less clear even though
therapy preserves bone mass and bone structure in these
women [7-9]. Because up to 50% of postmenopausal
women have osteopenia[2], and more than half of fragil-
ity fractures occur in these women[3], this issue is partic-
ularly relevant from a health policy perspective. A recent
study found that alendronate would likely not be consid-
ered cost-effective for the treatment of women with osteo-
penia diagnosed on the basis of BMD alone[17]. If only
fracture prevention is considered, alternative treatment
options such as raloxifene, calcitonin, or other bisphos-
phonates would be expected to have similarly unfavorable
cost-effectiveness profiles in women with osteopenia.
However, previous decision analyses have found that the
extraskeletal effects of raloxifene are important considera-
tions[21,41-45]. In the current study, assuming a societal
willingness-to-pay of $50,000 per QALY, raloxifene
would be considered cost-effective for 55 and 60 year old
women with T-scores in the lower half of the osteopenic
range. For 60 year old women with a 5-year risk of breast
cancer that is 50% greater than the population average,
raloxifene treatment would cost less than $50,000/QALY
for women throughout the osteopenic range (T-score
between -1 and -2.5). Examples of additional breast can-
cer risk factors that would increase the risk of 60 year old
women more than 50% include having at least 1 breast
biopsy with atypical hyperplasia or at least 1 first degree
relative with a history of breast cancer[44]. The extraskel-
etal effects of raloxifene contributed substantially to its
effectiveness, with the reduction in the incidence of breast
cancers contributing more to the gain in QALYs compared
to fracture prevention for women under the age of 75.
Cost-effectiveness thresholds for raloxifene treatment of  postmenopausal women at varying ages, T-score, and risk of  breast cancer Figure 2
Cost-effectiveness thresholds for raloxifene treat-
ment of postmenopausal women at varying ages, T-
score, and risk of breast cancer. Patient populations with 
a T-score worse or a breast cancer risk greater than that 
shown at each line would be considered cost-effective at the 
indicated societal willingess-to-pay. The influence of age is 
demonstrated by showing the $50,000/QALY threshold at 60 
and 70 years of age.
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Relative contributions of the skeletal and extraskeletal effects  of raloxifene Figure 1
Relative contributions of the skeletal and extraskele-
tal effects of raloxifene. The total expected effectiveness 
is the sum of the contributions from the reduced incidence 
of vertebral fractures and breast cancers minus the QALYs 
lost from the increased incidence of venous thromboembo-
lism. Abbreviations: QALY, quality-adjusted life year.
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The results for both alendronate and raloxifene were sen-
sitive to assumptions about cost and efficacy. Generic
alendronate is currently expected to become available in
2008 and if the price of alendronate drops to $1/day, the
cost-effectiveness ratio would be similar to that of
raloxifene for 60 year old women with a T-score of -1.8.
Consistent with a prior study[17], our findings suggest
that at its current price alendronate would not be consid-
ered cost-effective for osteopenic women unless it was
assumed to decrease the incidence of nonvertebral frac-
tures and restricted to use in women with bone mineral
densities nearly in the osteoporotic range.
Previous studies[21,41,43-45,47] have indicated that the
cost-effectiveness of raloxifene, which as of 2006 is indi-
cated only for the prevention and treatment of osteoporo-
sis, was driven largely by its associated extraskeletal
effects. Although most previous work has focused on
patients with osteoporosis[21,43-45], they have neverthe-
less demonstrated that the age, risk of fracture, and risk of
breast cancer of the target population are key considera-
tions. For example, a model of raloxifene versus placebo
found that for 60 year-old women approximately 80%
and 20% of overall QALYs gained from raloxifene were
attributable to breast cancer prevention and vertebral frac-
ture prevention, respectively, even for an osteoporotic
patient population[44]. Another study that modeled
healthy postmenopausal women found that raloxifene
would be considered a cost-effective alternative to hor-
mone replacement therapy (HRT)[41]. A decision analysis
that considered raloxifene, alendronate, or hormone
replacement therapy, gains in life expectancy were
dependent on a woman's individual risk profile for oste-
oporosis, breast cancer, and cardiovascular disease[42].
However, the latter two studies were completed prior to
the findings from the Women's Health Initiative (WHI)
Univariate sensitivity analyses for raloxifene Figure 3
Univariate sensitivity analyses for raloxifene. The black bars indicate increases and white bars indicate decreases in the 
incremental cost-effectiveness ratio. The values shown in parentheses correspond to the range of input values. Abbreviations: 
RRR, relative risk reduction; BrCa, breast cancer; Fx, fracture; VTE, venous thromboembolism.
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that demonstrated net harm with HRT in relatively
healthy postmenopausal women[48]. A comparative eco-
nomic analysis in a preventative setting that included the
WHI results found that raloxifene was more cost-effective
than alendronate, while hormone replacement therapy
would be predicted to result in net harm[47]. The current
study is the first that has incrementally compared
raloxifene and alendronate treatment in osteopenic
women.
Limitations
First, as with any simulation, the actual clinical situation
was simplified to avoid creating an overly complex model.
For example, common side effects such as gastrointensti-
nal upset for bisphosphonates and hot flashes or leg
cramps for raloxifene have not been considered. Second,
the usefulness of the results depends on the quality of the
model inputs and there was substantial uncertainty in sev-
eral of the parameters. We have addressed this issue
through sensitivity analyses but the results of these analy-
ses span a considerable range for some parameters. Third,
although the results were dependent on the patient popu-
lation's risk of developing invasive breast cancer, available
methods to calculate the patient's 5-year risk, such as the
Gail model[46], are not in widespread use and do not dis-
criminate which individual patients will develop breast
cancer[49]. However, for 60 year old women with T-scores
in the lower half of the osteopenic range, even when they
do not have an elevated risk of breast cancer for their age,
raloxifene compared favorably with the commonly used
benchmark of $50,000/QALY for a therapy to be consid-
ered cost-effective. Finally, the results apply only to post-
menopausal women with osteopenia who are otherwise
relatively healthy. A recently completed large clinical trial
demonstrated that, in women with coronary heart disease
(CHD) or an increased risk of CHD, raloxifene was not
associated with an increase or decrease in the incidence of
coronary events or stroke but there was an increase in
stroke mortality[50]. Osteonecrosis of the jaw (ONJ) is a
rare but serious adverse event associated with bisphos-
phonate use[51]. Most, although not all, cases of ONJ
have been reported in patients with multiple myeloma or
metastatic cancer[51]. We have not included stroke or
ONJ in the current model because women at an increased
risk for CHD or with cancer would be considered outside
the scope of the current study.
These results are not necessarily applicable to other
SERMs with different efficacy and safety profiles. For
example, tamoxifen has proven efficacy for reducing the
incidence of primary and recurrent breast cancer but is
also associated with an increased risk of endometrial can-
cer[52]. In the primary prevention setting, tamoxifen is
most cost-effective for younger women at increased risk of
breast cancer who have had a hysterectomy[52]. As new
SERMs are developed, the specific balance of skeletal (i.e.,
vertebral and nonvertebral risk reduction) and extraskele-
tal effects will require new analyses in order to understand
the most favorable patient population for each molecule.
An algorithm from the World Health Organization to
derive the absolute risk of fracture[54] based on a number
of clinical inputs is expected to be released in 2007. The
results of the current study, based on T-scores, should be
re-calibrated to consider a patient's absolute risk of frac-
ture to be comparable with future cost-effectiveness stud-
ies. However, advanced age is one of the most important
risk factors for fracture and was one of the variables exam-
ined here.
Conclusion
While the present study suggests that the use of raloxifene
to prevent fractures in postmenopausal women with oste-
openia may be cost-effective on a population level, the
optimal treatment decision for an individual patient will
depend upon her unique profile of risks for various posi-
tive and negative outcomes and values attributed to
potential health states, including that of taking a treat-
ment with evident side effects and largely unobservable
benefits. As our ability to estimate patient-specific disease
risks improves, the importance of integrating these risk
assessments and individualizing complex preventative
treatment decisions will grow.
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